Vicore Pharma Holding AB (publ)

DB:6Y4 Stock Report

Market Cap: €166.9m

Vicore Pharma Holding Valuation

Is 6Y4 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 6Y4 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 6Y4's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 6Y4's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 6Y4?

Key metric: As 6Y4 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 6Y4. This is calculated by dividing 6Y4's market cap by their current revenue.
What is 6Y4's PS Ratio?
PS Ratio18.5x
SalesSEK 104.24m
Market CapSEK 1.92b

Price to Sales Ratio vs Peers

How does 6Y4's PS Ratio compare to its peers?

The above table shows the PS ratio for 6Y4 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average9.4x
2INV 2invest
8.3xn/a€64.4m
HPHA Heidelberg Pharma
13.1x16.6%€110.9m
FYB Formycon
14.5x33.4%€882.8m
BIO3 Biotest
1.5x3.6%€1.3b
6Y4 Vicore Pharma Holding
18.5x61.7%€1.9b

Price-To-Sales vs Peers: 6Y4 is expensive based on its Price-To-Sales Ratio (18.5x) compared to the peer average (9.4x).

Price to Sales Ratio vs Industry

How does 6Y4's PS Ratio compare vs other companies in the DE Biotechs Industry?

7 CompaniesPrice / SalesEstimated GrowthMarket Cap
BIO3 Biotest
1.5x3.6%US$1.42b
CNW co.don
0.7xn/aUS$6.97m
V9Z Aceragen
0.4xn/aUS$3.12m
PA8 Paion
0.2x30.2%US$2.78m
6Y4 18.5xIndustry Avg. 8.0xNo. of Companies7PS0612182430+
7 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 6Y4 is expensive based on its Price-To-Sales Ratio (18.5x) compared to the European Biotechs industry average (8x).

Price to Sales Ratio vs Fair Ratio

What is 6Y4's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

6Y4 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio18.5x
Fair PS Ratio16.3x

Price-To-Sales vs Fair Ratio: 6Y4 is expensive based on its Price-To-Sales Ratio (18.5x) compared to the estimated Fair Price-To-Sales Ratio (16.3x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 6Y4 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€0.63
€2.95
+368.3%
21.1%€3.47€1.73n/a5
Nov ’25€0.64
€3.16
+395.3%
8.1%€3.52€2.81n/a4
Oct ’25€0.65
€3.20
+392.2%
9.1%€3.52€2.82n/a3
Sep ’25€1.37
€4.37
+219.6%
30.1%€6.05€2.77n/a4
Aug ’25€1.53
€5.33
+248.1%
31.0%€7.27€2.77n/a4
Jul ’25€1.85
€5.33
+187.5%
31.0%€7.27€2.77n/a4
Jun ’25€1.62
€5.33
+227.9%
31.0%€7.27€2.77n/a4
May ’25€1.51
€5.33
+253.1%
31.0%€7.27€2.77n/a4
Apr ’25€1.28
€5.33
+317.3%
31.0%€7.27€2.77n/a4
Mar ’25€1.22
€6.02
+394.4%
32.3%€8.51€2.81n/a5
Feb ’25€1.18
€5.96
+404.0%
34.4%€8.17€2.69n/a4
Jan ’25€1.28
€5.96
+365.4%
34.4%€8.17€2.69n/a4
Dec ’24€1.28
€5.96
+363.9%
34.4%€8.17€2.69n/a4
Nov ’24€1.08
€5.96
+452.6%
34.4%€8.17€2.69€0.644
Oct ’24€1.29
€5.96
+361.8%
34.4%€8.17€2.69€0.654
Sep ’24€1.30
€5.96
+359.6%
34.4%€8.17€2.69€1.374
Aug ’24€1.58
€5.98
+278.7%
34.4%€8.20€2.71€1.534
Jul ’24€1.48
€6.10
+313.0%
35.1%€8.39€2.68€1.854
Jun ’24€1.62
€6.44
+297.0%
31.0%€8.67€2.77€1.625
May ’24€1.69
€6.29
+271.9%
29.8%€8.71€2.78€1.516
Apr ’24€1.50
€6.29
+318.4%
29.8%€8.71€2.78€1.286
Mar ’24€1.24
€6.32
+409.8%
29.8%€8.76€2.80€1.226
Feb ’24€1.49
€6.67
+349.0%
31.2%€8.76€2.77€1.186
Jan ’24€1.60
€7.69
+381.0%
16.7%€9.03€5.53€1.285
Dec ’23€2.16
€7.69
+256.6%
16.7%€9.03€5.53€1.285
Nov ’23€2.70
€7.39
+174.2%
15.4%€8.91€5.51€1.085

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Aspen Pharmacare Holdings

R73.7b

Manufactures and supplies specialty and branded pharmaceutical products worldwide.

LDZA

R8.60

7D

-3.9%

1Y

-0.6%

Collegium Pharmaceutical

US$990.4m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

354

US$29.00

7D

1.4%

1Y

25.0%

Pharming Group

€492.8m

A biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally.

PHGN

€0.72

7D

-1.0%

1Y

-31.3%